Drugs and vaccines for COVID-19: List of authorized clinical trials

On this page

The tables below list the COVID-19-related clinical trials that have been authorized by Health Canada. These trials have been authorized through either:

This listing represents the initial authorization of the trial, but does not necessarily indicate that the trial is currently active. Status of the trial should be confirmed with the authorization holder.

Health Canada continues to discuss potential clinical trials with a number of sponsors. We will update the lists as new trials related to drugs or vaccines for COVID-19 are authorized.

List of COVID-19 vaccine trials

Table 1. List of COVID-19 vaccines currently in clinical trials authorized by Health Canada
Trial name /Protocol #/control # Title Interventions Authorization holder Authorization date Clinicaltrials.gov link
VBI-2901E (Control # 268572)
Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations
A Phase 1, Open-Label, Adjuvant Dose-Escalation, Randomized Study To Evaluate The Safety And Immunogenicity Of Vbi-2901e, A Trivalent Coronavirus Vaccine Candidate Adjuvanted With Aluminum Phosphate And E6020 In Healthy Adults Previously Vaccinated With Licensed Covid-19 Vaccines Vaccine:
VBI-2901E
Variation Biotechnologies Inc. 2022-10-25 N/A
COVAC-1 (Control # 267708)
Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations
A Randomized, Observer-Blind, Dose Escalation, Placebo-Controlled, Phase 1 Clinical Trial To Study The Safety And Immunogenicity Of A Covac-1 Booster Dose In Generally Healthy Adults Vaccine:
COVAC-1 (nCOV19 S1)
University of Saskatchewan 2022-09-28 N/A
VBI-2901A (Control # 267517)
Authorized under the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations
A Phase 1, Randomized Study To Evaluate The Safety And Immunogenicity Of VBI- 2901a, A Trivalent Coronavirus Vaccine Candidate In Healthy Adults Previously Vaccinated With Licensed Covid-19 Vaccines Vaccine:
VBI-2901A
Variation Biotechnologies Inc. 2022-09-15 N/A
COVB-2022-1 (Control # 261144) Authorized under the Clinical Trials Interim Order Covid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) SPIKEVAX (Elasomeran (mRNA)) / NUVAXOVID (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) CHU de Québec – Université Laval 2022-02-18 NCT05236491
CP-PRO-CoVLP-026
(Control # 259935)
Authorized under the Clinical Trials Interim Order
A Randomized, Partially-Blind, Multicenter, Phase 3 Study to Assess the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Homologous or Heterologous Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults Previously Vaccinated with a COVID-19 Vaccine Vaccines:
Coronavirus-like Particle (CoVLP) COVID-19 Vaccine / CoVLP.B1351 COVID-19 Vaccine
Medicago Inc. 2022-01-19 N/A
COVAC-004
(Control # 259104)
Authorized under the Clinical Trials Interim Order
A Phase 1/2 Clinical Trial to Study Safety, Tolerability, and Immunogenicity of a COVAC-2 Booster Dose in Generally Healthy Adults Vaccine: COVAC-2 (nCoV19 S1) University of Saskatchewan, VIDO 2021-12-23 NCT05226702
MP-37-2021-7562
(Control # 258049)
Authorized under the Clinical Trials Interim Order
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases Vaccines:
SPIKEVAX (Elasomeran (mRNA))
Research Institute of the McGill University Health Centre 2021-11-08 NCT04806113

M010
(Control # 257190)

Phase 1, Open Label Study to Evaluate the Safety and Immunogenicity of ChAd68 and AdHu5 vector-based Trivalent COVID-19 Vaccines Delivered Via Inhaled Aerosol ChAd-CoV/Mac / Ad5-CoV/Mac McMaster University 2021-10-21 NCT05094609

PRO-CL-002

(Control # 253878) Authorized under the Clinical Trials Interim Order
A Phase 2, Randomized, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegative Adults Aged 18 to 64 Years PTX-COVID19-B / Pfizer-BioNTech COVID-19 Vaccine Providence Therapeutics Holdings, Inc. 2021-07-20 N/A
3750
(Control # 255889)
Authorized under the Clinical Trials Interim Order
BOOST KIDNEY: A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 versus mRNA-1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response following COVID-19 Vaccination COMIRNATY Vaccine (BNT162b2 mRNA Covid-19 Vaccine) / SPIKEVAX Vaccine (mRNA-1273 SARS-CoV-2 Vaccine) Sunnybrook Research Institute 2021-09-02 NCT05022329
Moderna RCT LTCF
(Control # 255430)
Authorized under the Clinical Trials Interim Order
Third Dose of Moderna mRNA-1273 COVID-19 Vaccine in Residents of Long-Term Care Facilities Moderna COVID-19 vaccine (mRNA-1273 vaccine) McMaster University 2021-08-13 NCT04978038
mRNA-1273-P204
(Control #254169)
Authorized under the Clinical Trials Interim Order
A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age COVID-19 Vaccine Moderna (mRNA-1273 SARS-CoV-2 vaccine) ModernaTX, Inc 2021-07-08 NCT04796896
ALT-501-102
(Control # 252058)
Authorized under the Clinical Trials Interim Order
A Phase 1, Open-label Study to Evaluate the Effect of Position and Duration on the Safety and Immunogenicity of Intranasal AdCOVID Administration AdCOVID Vaccine Altimmune, Inc. 2021-05-26 N/A

CT24
(Control # 251972)
Authorized under the Clinical Trials Interim Order

Immunogenicity and adverse events following immunization (AEFI) with alternate schedules of COVID-19 vaccines in Canada: is “mix and match” of the second dose (MOSAIC-a;CT24a) and third dose (MOSAIC-2;CT24b) safe and immunogenic? Vaccines: Comirnaty Pfizer-BioNTech COVID-19 Vaccine, mRNA) / SpikeVax (Moderna Elasomeran mRNA vaccine) Dalhousie University/Canadian Immunization Research Network (CIRN) 2021-05-05 NCT04894435

KBP-201
(Control #251755)
Authorized under the Clinical Trials Interim Order

A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine with CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
TAP-COVID-19 Kentucky Bioprocessing, Inc. 2021-05-03 NCT04473690
UHN-TID-COVAX-2
(Control # 251583)
A randomised, single blind, controlled trial of a third dose of Moderna vaccine versus placebo in solid organ transplant recipients Moderna COVID-19 vaccine (mRNA-1273 SARS-CoV-2 vaccine) University Health Network 2021-04-26 NCT04885907
VAC31518COV2004
(Control # 250107)
Authorized under the Clinical Trials Interim Order
An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants Jcovden (Ad26.COV2.S (JNJ-78436735)) Janssen Inc. 2021-03-17 NCT04765384
Ad5-nCoV-2020003
(Control # 239283)
A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults from 18 to <85 years of age in Canada Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5) (Ad5-nCoV) CanSino Biologics Inc. 2020-05-15 NCT04398147
COBRA
(Control # 238868)
A Randomized, Double-blind, Placebo-Controlled Phase 3 Study: Efficacy and Safety of Recombinant BCG VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity Recombinant
Mycobacterium bovis
BCGΔureC::hly
Princess Margaret Cancer Centre 2020-05-08 NCT04439045
COVAC-001
(Control # 247198)
Authorized under the Clinical Trials Interim Order
A Randomized, Observer-Blind, Dose-Escalation Phase I Clinical Trial of COVAC-2 in Healthy Adults COVAC-2 (nCoV19 S1) University of Saskatchewan, VIDO 2020-12-22 NCT04702178
CP-PRO-CoVLP-019
(Control # 240922)
A Randomized, Partially-Blinded, dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-55 Years of Age Coronavirus-like Particle (CoVLP) COVID-19 Vaccine Medicago Inc. 2020-07-09 NCT04450004
CP-PRO-CoVLP-021
(Control # 245149)
Authorized under the Clinical Trials Interim Order
A Randomized, Observer-Blind, Placebo-Controlled Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older Coronavirus-like Particle (CoVLP) COVID-19 Vaccine Medicago Inc. 2020-11-09 NCT04636697
IC.8
(Control # 240586) Authorized under the Clinical Trials Interim Order
COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure IMM-101 Canadian Cancer Trials Group, Cancer Research Institute, Queen's University 2020-06-24 NCT04442048
PRO-CL-001
(Control # 246974)
Authorized under the Clinical Trials Interim Order
A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 PTX-COVID19-B Providence Therapeutics Holdings Inc. 2020-12-22 NCT04765436
VAC31518COV2001
(Control # 246908)
Authorized under the Clinical Trials Interim Order
A Randomized, Double-blind, Placebo-Controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive Jcovden (Ad26.COV2.S (JNJ-78436735)) Janssen Inc. 2020-12-14 NCT04535453
VBI-2902a-CT01
(Control # 246985)
Authorized under the Clinical Trials Interim Order
A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults VBI-2902a / VBI-2905a VBI Vaccines Inc. 2020-12-18 NCT04773665
ENTVAX01-101
(Control # 250321)
Authorized under the Clinical Trials Interim Order
Phase I/II Study to Evaluate Safety, Tolerability, Immunogenicity of a Prophylactic Plasmid DNA Vaccine against SARS CoV-2 (Covigenix VAX-001) in Healthy Adults 18 Years and Older Covigenix VAX-001 Entos Pharmaceuticals Inc. 2021-03-24 NCT04591184

List of COVID-19 treatment trials

Table 2. List of COVID-19 treatments currently in clinical trials authorized by Health Canada
Trial name /Protocol #/control # Title Interventions Authorization holder Authorization date Clinicaltrials.gov link
LAU-23-01 / control# 277639 A Double-Blind, Randomized, Placebo-Controlled, Adaptive, Phase 2/3 Study of the Efficacy of LAU-7B in the Treatment of Adults with Long COVID and Moderate to Severe Symptoms Fenretinide (LAU-7B) Laurent Pharmaceuticals 2023-08-22 N/A
GS-US-611-6549 / control# 277480 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 For the Treatment of F COVID-19 in Non-Hospitalized Participants Obeldesivir (GS-5245) Gilead Sciences Canada Inc. 2023-08-22 N/A
C4671028 / control# 271389 A Phase 1, Open-Label Randomized Study to Investigate the Safety and PK Following Multiple Oral Doses of PF-07321332 (Nirmatrelvir)/Ritonavir in Adult Participants with COVID-19 and Severe Renal Impairment either on Hemodialysis or Not on Hemodialysis PF-07321332 (Nirmatrelvir)/Ritonavir Pfizer Canada ULC 2023-03-29 N/A
OZUHN-004 / control# 271810 Platform Of Randomized Adaptive Clinical Trial in Critical Illness (PRACTICAL) Randomized Control Trial Dexamethasone University Health Network 2023-02-07 N/A

OZUHN-002 / control # 271420

Authorized under the COVID-19 Regulations

Recovering From COVID19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM) Pentoxifylline / Ibudilast (MN-166) University Health Network 2023-01-25 and 2023-02-03 NCT05513560

AT-03A-017 / control # 269964

Authorized under the COVID-19 Regulations

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEMNIFOSBUVIR IN HIGH-RISK OUTPATIENTS WITH COVID-19 BEMNIFOSBUVIR (BEM; AT-527) ATEA PHARMACEUTICALS INC. 2022-12-06 NCT05614349

CANTREATCOVID-1 / control # 269011

Authorized under the COVID-19 Regulations

CANADIAN ADAPTIVE PLATFORM TRIAL OF TREATMENTS FOR COVID IN COMMUNITY SETTINGS (CANTREATCOVID) NIRMATRELVIR / RITONAVIR UNITY HEALTH TORONTO 2022.11.02 NCT05614349
C4671042 /
control # 268341
An interventional, efficacy and safety, phase 2, randomized, double-blind, 2-arm study to investigate a repeat 5-day course of nirmatrelvir/ritonavir compared to placebo/ritonavir in participants at least 12 years of age with rebound of COVID-19 symptoms and rapid antigen test positivity Nirmatrelvir (PF-07321332)/ Ritonavir Pfizer Canada ULC 2022-10-28 N/A
GS-US-611-6273 / control # 267297 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GS-5245 FOR THE TREATMENT OF COVID-19 IN PARTICIPANTS WITH HIGH-RISK FOR DISEASE PROGRESSION GS-5245 Gilead Sciences Canada Inc. 2022-09-20 N/A
C4671034 / Control # 265231 AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3 ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NON-HOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID 19 WHO ARE IMMUNOCOMPROMISED NIRMATRELVIR (PF-07321332) / RITONAVIR PFIZER CANADA ULC 2022-08-02 N/A
H21-02254 Control # 263975 A DOUBLE BLIND RANDOMIZED TRIAL OF LOW-DOSE NALTREXONE FOR POST-COVID FATIGUE SYNDROME Treatment: NALTREXONE BRITISH COLUMBIA WOMENS HOSPITAL 2022-06-01 N/A
PTC299-VIR-015-COV19
(Control # 260607)
Evaluation of the efficacy and safety of PTC299 in hospitalized subjects with covid-19 (FITE19) EMVODODSTAT (PTC299) PTC THERAPEUTICS INC 2022-02-02 N/A
BCDF002
(Control # 255061)
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine For Cognitive Deficits in Persons with Post-COVID-19 Syndrome Vortioxetine Brain and Cognition Discovery Foundation 2021-08-17 N/A
CARDIOL 100-03
(Control #254314)
Study to Evaluate the Efficacy and Safety of CARDIOLRX in Patients with COVID-19 and Cardiovascular Disease or Risk Factors, a Double-Blind, Placebo-Controlled Trial (LANCER) Cannabidiol (CARDIOLRX) Cardiol Therapeutics Inc. 2021-07-16 NCT04615949
SAMI-06-1-01
(Control # 253521)
A Randomized, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects with Persistent Respiratory Symptoms S-1226 (Carbon Dioxide-Perflubon) Solaromed Inc. 2021-06-21 NCT04949386
COVID-NONS-05
(Control #
252713)
Multi-Center, Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) to Treat and Prevent the Exacerbation of Infection in Individuals with Documented Mild COVID-19 Nitric oxide Sanotize Research & Development Corp. 2021-05-25 N/A
20210072-01H
(Control #
251410)
Dietary supplements to reduce symptoms severity and duration in people with SARS-COV-2: A randomized, double-blind, placebo controlled clinical trial Vitamin D / Vitamin K-Vitamin D Ottawa Hospital Research Institute 2021-05-21 NCT04780061
WV43042
(Control #
252494)
A phase II randomized, double-blind, placebo controlled study to evaluate the antiviral activity safety, pharmacokinetics, and efficacy of RO7496998 (AT-527) in non-hospitalized adult patients with mild or moderate COVID-19 AT-527 (RO7496998) Hoffman La Roche Limited 2021-05-20 NCT04709835
EXTEND-P2
(Control #
246808)
Authorized under the Clinical Trials Interim Order
Extend (Novel oxygen therapeutic NANO2 for COVID-19) Phase IB/II trial Perflenapent (NANO2) Nuvox Pharna LLC 2021-05-17 N/A
COVID-NONS-04
(Control #
252244)
Decentralized, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection Nitric oxide Sanotize Research & Development Corp 2021-05-14 N/A
1000074027
(Control # 251634)
Lung Structure-Function in Survivors of Mild and Severe COVID19 Infection: 129XE MRI for Rapid Evaluation and Nextwave Healthcare Planning (LIVECOVIDFREE) Hyperpolarized Xenon-129 The Hospital for Sick Children 2021-04-29 N/A
CIRCA-19 RCT
(Control # 250736)
Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) Randomized Clinical Trial Allogeneic Umbilical Cord Mesenchymal Stromal Cells (UC-MSCs) Ottawa Hospital Research Institute 2021-04-13 NCT04400032
ACTIV-2/A5401
(Control # 250685)
Authorized under the Clinical Trials Interim Order
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) BRII-196 / BRII-198 / SAB-185/ BMS-986413/BMS-986414 / SNG001 (Interferon-β1a) / REGN10933 (Casirivimab)+REGN10987 (Imdevimab) National Institute of Allergy and Infectious Diseases (NIAID) 2021-04-08 NCT04518410
216912
(Control # 250948)
Authorized under the Clinical Trials Interim Order
A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants with Mild to Moderate Coronavirus Disease 2019 (COVID-19) VIR-7831 (GSK4182136) Vir Biotechnology Inc. 2021-04-09 NCT04779879
RVX222-CS-023
(Control # 250480)
An Open-Label Study to Assess the Safety and Effect on Clinical Course and Key Biomarkers of Oral Apabetalone in Hospitalized Subjects with COVID-19 Infection in Addition to Standard of Care (SOC) RVX000222 (Apabetalone) Resverlogix Corp 2021-04-06 N/A
CORE-COVID
(Control # 249936)
A Randomized Clinical Trial Comparing 7 Days Treatment with Corticosteroids Versus Placebo for Early COVID-19 Prednisone Governors of The University of Alberta 2021-03-08 N/A
CPI-006-003
(Control # 249442)
Authorized under the Clinical Trials Interim Order
Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized COVID-19 Patients CPI-006 Corvus Pharmaceuticals, Inc. 2021-03-01 NCT04734873
COVID-NORS-01
(Control # 247971)
The Efficacy of Topical Nitric Oxide Releasing Solutions (NORS) in the Management of Coronavirus Disease 2019 (COVID-19) Nitric Oxide St. Paul's Hospital Vancouver 2021-01-15 N/A
JF-12-2020
(Control # 247938)
TOGETHER-Toronto: A phase III randomized, double-blind, placebo-controlled, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 Peginterferon Lambda-1A University Health Network 2021-01-13 N/A
SAMI-05-1-01
(Control # 247617)
A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 in Hospitalized Subjects with Moderate Severity COVID-19 S-1226 (Carbon-Dioxide Perflubron) Solaeromed Inc. 2020-12-31 N/A
REDA-10122
(Control #248696)
Authorized under the Clinical Trials Interim Order
Annexin A5 in Patients with Severe COVID-19 Disease SY-005 (Recombinant Human Annexin A5) Lawson Health Research Institute 2021-02-05 NCT04748757
115769
(Control # 238857)
Safety and Efficacy of Post-Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the prevention of Corona Virus Infectious Disease-19 (COVID-19) in high-risk patients/residents in Institutions Hydroxychloroquine St. Joseph's Health Care Parkwood site 2020-05-09 NCT04371523
20-5449
(Control # 239579)
Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted with COVID-19 Nitric oxide University Health Network 2020-06-25 NCT04383002
2021-6954
(Control # 244461)
Authorized under the Clinical Trials Interim Order
Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans): a Randomized Phase II Controlled Clinical Trial ProTrans (Wharton's Jelly derived Umbilical Cord Mesenchymal Stromal Cells (UCMSC) Research Institute of the McGill University Health Centre 2020-10-16 NCT04869397
2021-7362
(Control # 246471)
Fluvoxamine for Early Treatment of COVID-19: A Fully Remote, Randomized Placebo Controlled Trial (STOP COVID 2 Canada) Fluvoxamine Research Institute of the McGill University Health Centre 2020-11-30 NCT04668950
2149
(Control # 240138)
Authorized under the Clinical Trials Interim Order
Sedating with Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters and Survival; Multicentre Open-Label, Pragmatic, Randomised Controlled Trial and a Parallel Prospective (Non-Randomised) Cohort Study Isoflurane, sevoflurane Sunnybrook Research Institute 2020-06-10 NCT04415060
776228483 PROACTIVE
(Control # 240296)
Propranolol as an Anxiolytic to Reduce the Use of Sedatives for Critically Ill Adults Receiving Mechanical Ventilation: an Open-Label Randomized Controlled Trial. (PROACTIVE) Propranolol Ottawa Hospital Research Institute 2020-06-10 NCT04467086
AB002
(Control # 238815)
Multicentre, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of LSALT PEPTIDE as Prevention of Acute Respiratory Distress Syndrome (ARDS) in Patients Infected with SARS-COV-2 (COVID-19) LSALT Peptide Arch Biopartners Inc. 2020-05-07 NCT04402957
AGN120-3
(Control # 238605)
A Randomized Open Label Phase 2/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients. NP-120 (fenprodil) Algernon Pharmaceuticals 2020-04-29 NCT04382924
AP-RECAP-AKI-03-01
(Control # 243263)
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel-Group, Multi-Center Phase 3 Pivotal Trial to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients with Sepsis Associated Acute Kidney Injury Recombinant human alkaline phosphatase AM-PHARM A B.V. 2020-09-11 NCT04411472
ARBS CORONA II
(Control # 243532)
Authorized under the Clinical Trials Interim Order
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There A Protective Effect of Losartan on Outcomes of Coronavirus Infection? Losartan Providence Health Care Saint Paul's Hospital 2020-09-28 NCT04606563
ATI0320
(Control # 244962)
Favipiravir for Post Exposure Prophylaxis in SARS-COV2-exposed Vulnerable Individuals (PEPCO) Double-blinded, Placebo-Controlled, Randomized, Multinational, Phase-3 clinical Trial to Evaluate the Efficacy of Favipiravir in Preventing the Development of COVID-19 When Given to Asymptomatic SARS-CoV2-Negative Individuals Who Had Direct Exposure to a SARS-CoV2 Infected Person. Favipiravir Appili Therapeutics Inc. 2020-11-02 N/A
BAI_COV19_01
(Control # 239071)
Inhaled NO For The Treatment of COVID-19 Caused by SARS-CoV-2 Nitric oxide Beyond Air. Inc. 2020-05-19 NCT04456088
BHC-RIB 5401-HC
(Control # 238007)
An Open Label Study to Evaluate the Safety and Efficacy of Virazole® (ribavirin for inhalation solution, USP) in Hospitalized Adult Participants with Respiratory Distress Due to COVID-19 Virazole® (ribavirin) Valeant Canada LP/Valeant Canada S.E.C. 2020-04-08 NCT04356677
CATCO
2114
(Control # 237108)
The Canadian arm of the WHO SOLIDARITY Trial.
A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients.
Artesunate/ imatinib/ infliximab/ losartan/ dexamethasone
Sunnybrook Research Institute 2020-03-18 NCT04330690
CIAO_COVID20
(Control # 246983)
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial Xolair (omalizumab) The Research Institute of the McGill University Health Centre 2020-12-21 N/A
CINC424J12301 RUXCOVID
(Control # 240395)
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Ruxolitinib in Patients with COVID-19 Associated Cytokine Storm (RUXCOVID) Jakavi (ruxolitinib) Novartis Pharmaceuticals Canada Inc. 2020-06-16 NCT04362137
CIRCA-19
(Control # 238608)
Cellular Immunotherapy for COVID-19 acute Respiratory Distress Syndrome (ARDS) Allogeneic Umbilical Cord Mesenchymal Stromal Cells (UC-MSC) Ottawa Hospital Research Institute 2020-05-15 NCT04400032
COLCORONA
MHIPS-2020-001
(Control # 237317)
Colchicine coronavirus SARS-COV2 trial (COLCORONA) Colchicine Montreal Heart Institute 2020-03-20 NCT04322682
CONCOR-Kids
(Control # 238820)
CONCOR-KIDS: A Randomized, Multicentered, Open-Label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus-Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Apheresis frozen plasma from recovered COVID-19 patients (convalescent plasma) C17 Council 2020-05-04 NCT04377568
CONTROL-COVID-Favipiravir-1
(Control # 239133)
Control of COVID-19 Outbreak in Long Term Care Favipiravir Appili Therapeutics Inc. 2020-05-18 NCT04448119
CORIPREV-1
(Control # 237350)
COVID-19 Ring-Based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR). Lopinavir/ Ritonavir Unity Health Toronto 2020-03-21 NCT04321174
COV-01
(Control # 242568)
Authorized Under the Clinical Trials Interim Order
Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients Taltz (ixekizumab) / Otezla (apremilast) Amgen Canada Inc. 2020-08-20 NCT04590586
COVACTA
(Control #: 237397)
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia. Actemra®/RoActemra®
(tocilizumab)
Hoffmann-La Roche Limited 2020-03-25 NCT04320615
COVID-CTP-01 (Control # 237786) Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating NORS Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers & Individuals at Risk of Infection Nitric oxide Sanotize Research & Development Corp. 2020-04-18 NCT04337918
COVID-CTP-02 (Control #240702) Multi-center, Double-Blinded Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS to Treat and Prevent the Exacerbation of Infection in Individuals with Documented Mild COVID-19 Nitric oxide Sanotize Research & Development Corp. 2020-06-30 NCT04443868
COVID19 PEP RCT - Canada
2020-6549
(Control #237355)
Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial (COVID19 PEP RCT - Canada) Hydroxychloroquine Research Institute of the McGill University Health Centre 2020-03-25 NCT04308668v
CTO-3212
(Control # 244591)
Authorized under the Clinical Trials Interim Order
Evaluation of The Potential Benefit of Reninangiotensin System Inhibitors (RASI, ACEI/ARB) in High-Risk Patients with COVID-19 Cadesartan / valsartan / ramipril / perindopril / irbesartan / losartan / enalapril / captopril Ottawa Heart Institute Research Corporation 2020-10-16 NCT04591210
CTSN-MSC-ARDS001
(Control # 241138)
Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome Remestemcel-L Mesoblast, Inc. 2020-07-31 NCT04371393
D1690C00081
(Control # 240352)
Authorized under the Clinical Trials Interim Order
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19 Dapagliflozin Saint Luke's Hospital of Kansas City 2020-07-04 NCT04350593
DAL-401
(Control # 246298)
Authorized under the Clinical Trial Interim Order
A Double-Blind, Placebo-Controlled Phase 2A Proof-of-Concept trial of Dalcetrapid in Patients with Confirmed Mild to Moderate COVID-19 Dalcetrapid DalCor Pharma UK Ltd 2020-11-26 NCT04676867
DISCONNECT-1
(Control # 241689)
Dismantling COVID Induced Neutrophil ExtraCellular Traps (DISCONNECT-1): Phase I pilot study investigating the safety and feasibility of inhaled rhDNase1 and its impact on neutrophil extracellular traps (NETs) in non-ventilated COVID-19 infected patients Pulmozyme (dornase alfa) The Research Institute of the McGill University Health Centre 2020-07-24 NCT04409925
EB05-04-2020
(Control # 239462)
Authorized under the Clinical Trials Interim Order
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + Standard of Care (SOC) Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 EB05 Edesa Biotech Research Incorporated 2020-06-12 NCT04401475
EXTENDED-P2
(Control # 240041)
EXTENDED (Novel Oxygen Therapeutic NaN02 for COVID-19 induced ARDS) Phase IIa Trial Perflenapent (NaNO2)

Nuvox Pharna LLC

2020-06-10 N/A
FAST-1
(Control# 244310)
Authorized under the Clinical Trials Interim Order
Nebulized Furosemide For Pulmonary Inflammation in Intubated Patients with COVID-19 - A Phase 2/3 Study Furosemide Kingston Health Science Centre 2020-10-13 NCT04588792
FIRH_XE006
(Control # 245507)
Lung Structure-Function in Survivors of Mild and Severe COVID19 Infection : 129XE MRI and CT For Rapid Evaluations and Next Wave Healthcare Planning Hyperpolarized Xenon-129 St. Joseph's Healthcare Hamilton 2020-11-05 N/A
GRAAL-2020-01
(Control # 238201)
A Randomized, Open-Label Trial of Convalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1) Apheresis frozen plasma from recovered COVID-19 patients (convalescent plasma) Hamilton Health Sciences 2020-04-16 NCT04348656
GS-US-540-5821
(Control # 238163)
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-COV2 (COV) Infection Remdesivir Gilead Sciences Canada Inc. 2020-04-15 NCT04323761
HEROS-1
(Control # 237851)
Protecting Frontline Health Care Workers from COVID-19 with hydroxychloroquine Pre-Exposure Prophylaxis: A randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada Hydroxychloroquine University Health Network 2020-04-03 NCT04374942
HOPE
ABCOV-01
(Control # 237739)
A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of oral hydroxychloroquine for the treatment of SARS-CoV-2 positive patients for the prevention of severe COVID-19 disease (Short title: ALBERTA HOPE COVID-19) Hydroxychloroquine University of Calgary 2020-04-09 NCT04329611
JF-4-2020
(Control # 238558)
Interferon Lambda for Immediate Antiviral therapy at Diagnosis (ILIAD): A phase II randomized, double-blind, placebo-controlled, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19 Peginterferon Lambda-1A University Health Network 2020-04-29 NCT04354259

JH-COR-003
(Control # 246575)

Authorized under the Clinical Trials Interim Order with Terms and Conditions

NOVATION-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 Novaferon (chimeric interferon α) Genova Inc. 2020-12-11 NCT04669015
LAU-20-01
(Control #238614)
A Double-Blind, Randomized, Placebo-Controlled, Pilot Phase II Study of the Efficacy and Safety of Lau-7B in the Treatment of Adult Hospitalized Patients with COVID-19 Disease LAU-7B (fenretinide) Laurent Pharmaceuticals 2020-05-02 NCT04417257
9890
(Control #238851)
Exogenous Surfactant Administration for Patients with COVID-19 BLES (bovine lipid extract surfactant suspension) St. Joseph's Health Centre London 2020-05-05 NCT04375735
LOVIT-COVID MP-31-2021-3741
(Control #239705)
Lessening Organ Dysfunction with VITamin C - COVID (LOVITCOVID) Vitamin C Centre de recherche du centre hospitalier universitaire de Sherbrooke 2020-06-05 NCT04401150
Mild-CONTAIN
2021-6638
(Control # 239123)
Mild - CONTAIN CiclesOnide clinical Trial COVID-19 Treatment Ciclesonide Research Institute of the McGill University Health Centre 2020-05-23 N/A
MK-4482-001
(Control # 244315)
Authorized under the Clinical Trials Interim Order
A Phase 2/3 Randomized, Placebo Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19. MK-4482 Merck Canada Inc. 2020-10-19 NCT04575597
MK-4482-002
(Control # 244159)
Authorized under the Clinical Trials Interim Order
A Phase 2/3 Randomized, Placebo Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. MK-4482 Merck Canada Inc. 2020-10-19 NCT04575584
MP-31-2019-2945
(Control # 237164)
Lessening Organ Dysfunction with Vitamin C (LOVIT) Vitamin C
(ascorbic acid)
Centre de recherche du centre hospitalier universitaire de Sherbrooke 2020-03-18 NCT03680274
MP-37-2021-6659
(Control #238811)
A Multi-Centre, Randomized, Blinded, Placebo Controlled Clinical Trial of the Safety and Effectiveness of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Children Hydroxychloroquine Research Institute of the McGill University Health Centre 2020-05-04 N/A
MUHC_CAMOSTAT MESILATE
(Control #240313)
The Impact of the Camostat Mesilate on COVID-19 Infection: A Randomized Controlled Phase II Clinical Trial Camostat McGill University Health Centre 2020-07-02 N/A
NCT04405102
(Control # 241148)
A Randomized trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - a Pilot Trial (COZI) Ozanimod Institut universitaire de cardiologie et de pneumologie de Québec 2020-07-13 NCT04405102
NTM-CTP-01
(Control # 236728)
An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents with Non-Tuberculous Mycobacteria Nitric oxide Dr. Jeremy Road 2020-03-19 NCT03331445
OHRI-HBOT-001
(Control # 242108)
Multicentre Randomized Controlled Trial of Hyperbaric versus Normobaric oxygen therapy for COVID-19 Patients Oxygen Ottawa Hospital Research Institute 2020-07-30 NCT04500626
ONV2020-003
(Control# 243886)
Authorized under the Clinical Trials Interim Order
A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Centre, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol) in Healthy COVID-19 Vaccinated Adults Hiltonol (Polyriboinosinic acid-polyribocytidylic acid (Poly-ICLC)) Oncovir, Inc. 2020-09-25 NCT04672291
OZM-113 (Control # 238691) Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in collaboration with Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) Innohep (tinzaparin sodium) / Lovenox (enoxaparin sodium) / Fragmin (dalteparin sodium) / heparin sodium University of Manitoba 2020-04-29 NCT04372589
PDC01
(Control #242430)
A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety & Efficacy of Dapsone on the Treatment of COVID-19 Positive Patients Dapsone Research Institute of the McGill University Health Centre 2020-08-20 N/A
PHRI.ACT.COVID19
(Control # 238157)
Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT), a Randomized Trial Colchicine / acetylsalicylic acid / rivaroxaban Hamilton Health Sciences 2020-04-18 NCT04324463
PREP2020
(Control #238396)
Pre-Exposure Prophylaxis fro SARS-Coronovirus-2: A Pragmatic Randomized Clinical Trial Hydroxychloroquine University of Manitoba 2020-04-21 N/A
PRO00100606
(Control # 240943)
Improving Vitamin D Status in the Management of COVID-19 Vitamin D Governors of the University of Alberta 2020-07-27 NCT04385940
PROTECT
(Control # 243196)
Prevention of COVID-19 with Oral Vitamin D Supplemental Therapy in Essential Healthcare Teams Cholecalciferol Centre Hospitalier Universitaire Sainte-Justine 2020-09-16 NCT04483635
Protocol 214094
(Control # 239770)
A Randomized, Double-blind, Placebo-Controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients with Severe Pulmonary COVID-19 Related Disease GSK3196165 (otilimab) GlaxoSmithKline 2020-05-27 NCT04376684
RAPID COVID COAG
(Control #238510)
Coagulopathy of COVID-19: A pragmatic randomized controlled trial of therapeutic anticoagulation versus standard care as a rapid response to the COVID-19 pandemic (RAPID COVID COAG) Fondaparinux / Innohep / Fragmin / Lovenox / Lovenox HP / Heparin sodium injection / Heparin sodium and 0.9% sodium chloride injection / Heparin sodium in 5% dextrose injection Unity Health Toronto 2020-04-24 NCT04362085
REB20-0713
(Control # 239287)
A Prospective, Observational Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin 6 Receptor Antibody Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation related Mortality in SARS-Cov2 Positive Patients Actemra (tocilizumab) University of Calgary 2020-05-22 NCT04423042
REMAP-CAP
X17-0199
(Control # 237719)
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP):
Pandemic appendix to the core protocol
Heparin sodium/Lovenox/ Fragmin/ Innohep/ vitamin C/ simvastatin/ acetylsalicylic acid/ticagrelor/ clopidogrel/ ramipril/ lisinopril/ perindopril erbumine/ enalapril/ trandolapril, captopril/ losartan potassium/ valsatan, candesartan cilexetil/ irbesartan/ telmisartan/ olmesartan medoxomil Unity Health Toronto 2020-04-01 NCT02735707
ROB0050
(Control # 246389)
Lung Structure-Function in survivors of mild and severe COVID-19 Infection: 129XE MRI and CT for rapid evaluation and next-wave Healthcare Hyperpolarized Xenon-129 Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University 2020-11-27 NCT04584671
SAIL-004
(Control # 237708)
Assessment of Investigational Medications adjunct to Clinical Standard of Care for Treatment of Moderate to Severe Coronavirus Disease (COVID-19) Baricitinib/tocilizumab Dr. Lisa Barrett 2020-04-14 NCT04321993
SAR153191
(Control # 237332)
An Adaptive Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19 Kevzara® (sarilumab) Sanofi-Aventis Canada Inc. 2020-03-24 NCT04315298
U-DEPLOY
(OZUHN-001/ Sub-protocol # OZUHN-001-6)
(Control # 237848)
Umbrella Trial Defining Coordinated Approach to Pandemic Trials of COVID-19 and Data Harmonization to Accelerate Discovery Placenta derived decidual stromal cells (DSC) University Health Network 2020-04-07 NCT04331665
UHNSEMPATICO1
(Control # 244389)
Semaglutide to reduce Myocardial injury in Patients with COVID-19 Ozempic (semaglutide) University Health Network 2020-10-07 NCT04615871
VASCEPA-COVID-19 CARDIOLINK-9
(Control # 239025)
An Investigation on the Effects of Icosapent Ethyl (Vascepa™) on Inflammatory Biomarkers in Individuals with COVID-19 Cardiolink-9 (Vascepa™) (icosapent) Canadian Medical and Surgical Knowledge Translation Research 2020-05-08 NCT04412018
VIR-7831-5001
(Control # 244708)
Authorized under the Clinical Trials Interim Order
A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-Hospitalized Patients VIR-7831 Vir Biotechnology, Inc. 2020-10-13 NCT04545060

CAM-001

(Control # 247212)

Efficacy of Camostat Mesilate in Reducing Severity of COVID-19 Camostat/Candesartan Vancouver General Hospital 2021-03-22 N/A

Page details

Date modified: